alendronate has been researched along with paclitaxel in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Stearns, ME; Wang, M | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Erez, R; Miller, K; Satchi-Fainaro, R; Segal, E; Shabat, D | 1 |
| Benayoun, L; Eldar-Boock, A; Miller, K; Polyak, D; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
| Clementi, C; Mero, A; Miller, K; Pasut, G; Satchi-Fainaro, R | 1 |
| Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y | 1 |
| Panarelli, NC | 1 |
| Chang, Q; Geng, R; Kong, X; Qu, D; Wang, S | 1 |
| Bi, D; Guo, Y; Han, M; Qi, X; Wang, X; Yue, F; Zhao, L | 1 |
| Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI | 1 |
2 review(s) available for alendronate and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced injury in the gastrointestinal tract.
Topics: Alendronate; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Cation Exchange Resins; Colchicine; Ferrous Compounds; Gastrointestinal Diseases; Gastrointestinal Tract; Gout Suppressants; Humans; Imidazoles; Immunosuppressive Agents; Mycophenolic Acid; Paclitaxel; Polystyrenes; Tetracycline; Tetrazoles | 2014 |
11 other study(ies) available for alendronate and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Lumbar Vertebrae; Male; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Prostatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 1996 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Bridged-Ring Compounds; Cathepsin B; Cells, Cultured; Humans; Paclitaxel; Polymers; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukocyte Count; Mice; Mice, Inbred BALB C; Paclitaxel | 2011 |
Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms.
Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dendrimers; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Paclitaxel; Polyethylene Glycols; Rats | 2011 |
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Fluorescein-5-isothiocyanate; Human Umbilical Vein Endothelial Cells; Humans; Mice; Micelles; Neovascularization, Physiologic; Paclitaxel; Polyethylene Glycols; Tibia; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Liposomes; Mice; Mice, Inbred ICR; Mice, Nude; Multiple Myeloma; Paclitaxel; Phosphatidic Acids; Phosphatidylethanolamines; Transferrin; Xenograft Model Antitumor Assays | 2016 |
Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy.
Topics: Albumins; Alendronate; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Female; Indoles; Mice; Mice, Inbred BALB C; Nanoparticles; Osteosarcoma; Paclitaxel; Polymers; Surface Properties; Tissue Distribution | 2019 |
Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Folic Acid; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties | 2020 |